Despite strong scientific foundations, Life Sciences companies can face periods of underperformance driven by portfolio misalignment, declining franchises, regulatory setbacks, or operational inefficiencies. The consequences of delayed action are severe: eroded market share, missed innovation opportunities, and weakened stakeholder confidence. Turnaround and restructuring are particularly critical in sectors with long product development cycles and high capital intensity, such as Pharma, Biotech, MedTech, Diagnostics and CDMOs. A well-executed restructuring enables organizations to focus on high-value assets, optimize cost structures, realign manufacturing and commercial operations, and adapt to evolving market dynamics. It also safeguards the company’s ability to continue delivering critical therapies, devices, or diagnostic solutions to patients. In a changing healthcare environment, a proactive and strategic approach to turnaround and restructuring can transform potential decline into renewed growth, competitive advantage, and stronger organizational resilience.
We partner with Life Sciences organizations to design and execute turnaround and restructuring strategies that are both decisive and sustainable. Our approach begins with a comprehensive diagnostic of the business, assessing portfolio performance, cost structure, operational and manufacturing efficiency, and market positioning. We identify priority interventions, from divestments and R&D reprioritization to commercial optimization and organizational redesign. We also support scenario modeling to balance short-term cash preservation with long-term strategic value creation. Our team works closely with leadership to implement targeted action plans, establish robust governance, and engage stakeholders, ensuring changes are understood and executed across the organization. Whether helping a Pharma company stabilize a mature franchise, guiding a CDMO through manufacturing rationalization, or enabling a Diagnostics business to reallocate resources toward high-potential innovation, we combine sector-specific insight with pragmatic execution. The result is a clear path to financial recovery, operational efficiency, and renewed strategic focus, while maintaining patient access and preserving long-term value creation.
